On Monday, Barclays adjusted its outlook on shares of Arcus Biosciences (NYSE:RCUS), a company specializing in cancer therapies. The firm reduced the price target on the stock to $25.00, a decrease from the previous target of $35.00. Despite this change, Barclays maintained an Overweight rating on the shares.
The decision to lower the price target came after considering the results from a related trial by Roche. The trial, named SKY-06, evaluated an anti-TIGIT molecule in the first-line treatment of non-small cell lung cancer (NSCLC) and did not meet its expected outcomes. In response, Barclays chose to exercise caution and adjust their financial model for Arcus Biosciences.
Barclays' revised estimates reflect a more conservative forecast for Arcus' NSCLC programs, directly influenced by the recent clinical trial results. The firm's analyst has stated that the reduction in the price target is a precautionary measure to de-risk their investment model in light of the new data.
Despite the lowered price target, Barclays continues to express confidence in the potential of Arcus Biosciences. The firm's analyst emphasized a belief in the significant upside of the stock, reiterating the Overweight rating. This rating suggests that Barclays expects the stock to outperform the average total return of the stocks in the analyst's coverage sector over the next 12 to 18 months.
The updated price target and rating reflect Barclays' current stance on Arcus Biosciences based on the available information and recent developments within the industry.
In other recent news, Arcus Biosciences reported a GAAP revenue of $145 million and cash reserves of $1.1 billion in Q1 2024. The company also revealed plans for a Phase 3 trial of its HIF-2alpha inhibitor casimersen in early 2025.
Meanwhile, the company's Phase 3 STAR-121 study, which is similar in design to Roche's halted SKYSCRAPER-06 trial, raised concerns about the potential efficacy of Arcus's TIGIT program in non-small cell lung cancer.
Despite this, Cantor Fitzgerald maintained an Overweight rating on Arcus Biosciences, shifting focus to upper gastrointestinal cancers as a more promising opportunity for Arcus's TIGIT program.
Truist Securities, Barclays, and Citi also retained positive ratings for Arcus Biosciences, with Truist Securities adjusting its price target to $44, and Citi reaffirming its Buy rating with a price target of $38. Barclays maintained its Overweight rating with a steady price target of $35. These developments reflect recent progress and challenges in Arcus Biosciences' research and clinical trials.
InvestingPro Insights
As Barclays adjusts its outlook on Arcus Biosciences, real-time data from InvestingPro provides additional context to the company's financial health and market performance. With a market capitalization of approximately $1.29 billion and a notable revenue growth of 99.16% in the last twelve months as of Q1 2024, Arcus Biosciences demonstrates significant potential in its market sector.
Despite challenges such as a negative gross profit margin of -55.27% and an operating income margin of -105.49% in the same period, the company holds more cash than debt on its balance sheet, which could be a sign of financial resilience.
InvestingPro Tips highlight that analysts anticipate sales growth in the current year for Arcus Biosciences, yet they do not expect the company to be profitable this year. Additionally, while the stock has experienced a notable decline over the last week, Arcus' liquid assets exceed short-term obligations, indicating a degree of liquidity that may reassure investors.
For those interested in a deeper analysis, InvestingPro offers a comprehensive list of tips; there are 5 additional InvestingPro Tips available for Arcus Biosciences, which can be explored further for informed investment decisions. Utilize the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription for access to these valuable insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.